Crohn's disease

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

News

AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease appro...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new ind

News

Third positive trial sets up filings for AbbVie's Rinvoq in ...

AbbVie's would-be blockbuster Rinvoq has notched up another positive trial in Crohn's disease, showing that it can achieve clinical remission over a full year when used as a maintenance the

News

Takeda bags Japanese approval for Crohn's cell therapy Alofi...

Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.

News

Crowded psoriasis market cuts Lilly's mirikizumab ambitions

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file it for psoriasis as the market is getting much too congested.

News

AbbVie/Allergan merger cleared in EU with brazikumab sell-of...

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen

Merck fires up a $10.8bn Prometheus takeover bid

AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease appro...

Third positive trial sets up filings for AbbVie's Rinvoq in ...

Takeda bags Japanese approval for Crohn's cell therapy Alofi...

Crowded psoriasis market cuts Lilly's mirikizumab ambitions

AbbVie/Allergan merger cleared in EU with brazikumab sell-of...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Crohn's disease

Editor's Picks